Clinical Trial Technology Opportunity Assessment

A senior director in R&D at an F100 pharma company wanted to conduct a landscape analysis of technology trends and innovation impacting Phase 3 clinical trials in immunology to improve speed, effectiveness, and patient/provider experience.

BTG delivered a digital health strategy consultant with 20+ years of diverse strategic advisory, market access, and competitive intelligence experience. The consultant had previously spearheaded a range of initiatives for top biopharma companies to inform digital health and launch strategies. On this project, the consultant identified key players and areas of opportunity, anticipated disruptive competitor developments, and pinpointed ways to achieve competitive advantage. The output delivered by the talent served to inform the digital health strategy for the Immunology R&D team.

Previous Article
Portfolio Reporting Lead and Data Translator
Portfolio Reporting Lead and Data Translator

The Global Portfolio Management team of an F100 consumer healthcare company was in the midst of developing ...

Next Article
Urology Therapy Commercial Analytics
Urology Therapy Commercial Analytics

The medical specialties insights and analytics team of a multinational pharmaceutical company was understaf...